Cargando…

Inflammatory Bowel Diseases and COVID-19: The Invisible Enemy

Detalles Bibliográficos
Autores principales:	D’Amico, Ferdinando, Peyrin-Biroulet, Laurent, Danese, Silvio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	by the AGA Institute 2020
Materias:	Selected Summary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7161529/ https://www.ncbi.nlm.nih.gov/pubmed/32305331 http://dx.doi.org/10.1053/j.gastro.2020.04.032

Ejemplares similares

Adaptive Designs: Lessons for Inflammatory Bowel Disease Trials
por: D’Amico, Ferdinando, et al.
Publicado: (2020)

Inflammatory Bowel Disease Management During the Coronavirus-19 Outbreak: A Survey From the European Crohn’s and Colitis Organization
por: D’Amico, Ferdinando, et al.
Publicado: (2020)

Systematic Review on Inflammatory Bowel Disease Patients With Coronavirus Disease 2019: It Is Time to Take Stock
por: D’Amico, Ferdinando, et al.
Publicado: (2020)

Views of patients with inflammatory bowel disease on the COVID-19 pandemic: a global survey
por: D'Amico, Ferdinando, et al.
Publicado: (2020)

Landscape of new drugs and targets in inflammatory bowel disease
por: Vieujean, Sophie, et al.
Publicado: (2022)

Abdominal Pain in Inflammatory Bowel Diseases: A Clinical Challenge
por: Wils, Pauline, et al.
Publicado: (2022)

The European Perspective and History on Biosimilars for the Treatment of Inflammatory Bowel Diseases
por: Solitano, Virginia, et al.
Publicado: (2021)

Oral Iron for IBD Patients: Lessons Learned at Time of COVID-19 Pandemic
por: D’Amico, Ferdinando, et al.
Publicado: (2020)

Disease clearance in ulcerative colitis: Is the ultimate therapeutic target?
por: D’Amico, Ferdinando, et al.
Publicado: (2023)

Ustekinumab in Crohn’s Disease: New Data for Positioning in Treatment Algorithm
por: D’Amico, Ferdinando, et al.
Publicado: (2022)

Evolution of IL-23 Blockade in Inflammatory Bowel Disease
por: Danese, Silvio, et al.
Publicado: (2022)

Diarrhea During COVID-19 Infection: Pathogenesis, Epidemiology, Prevention, and Management
por: D’Amico, Ferdinando, et al.
Publicado: (2020)

Reply
por: D’Amico, Ferdinando, et al.
Publicado: (2020)

Reply
por: D’Amico, Ferdinando, et al.
Publicado: (2021)

Reply
por: D’Amico, Ferdinando, et al.
Publicado: (2021)

Balancing Risks and Benefits in Inflammatory Bowel Disease Patients during the COVID-19 Pandemic
por: Kotze, Paulo Gustavo, et al.
Publicado: (2021)

Setting up a Virtual Calprotectin Clinic in Inflammatory Bowel Diseases: Literature Review and Nancy Experience
por: D’Amico, Ferdinando, et al.
Publicado: (2020)

Selective Tyrosine Kinase 2 Inhibition for Treatment of Inflammatory Bowel Disease: New Hope on the Rise
por: Danese, Silvio, et al.
Publicado: (2021)

Which MRI Score and Technique Should Be Used for Assessing Crohn’s Disease Activity?
por: D’Amico, Ferdinando, et al.
Publicado: (2020)

SARS-CoV-2 vaccination in IBD: more pros than cons
por: D’Amico, Ferdinando, et al.
Publicado: (2021)

Positioning Filgotinib in the Treatment Algorithm of Moderate to Severe Ulcerative Colitis
por: D’Amico, Ferdinando, et al.
Publicado: (2021)

Can we change the natural course of inflammatory bowel disease?
por: Le Berre, Catherine, et al.
Publicado: (2023)

Novel Therapies and Approaches to Inflammatory Bowel Disease (IBD)
por: Furfaro, Federica, et al.
Publicado: (2022)

Rediscovering histology: what is new in endoscopy for inflammatory bowel disease?
por: Solitano, Virginia, et al.
Publicado: (2021)

Patient and Public Involvement in Research: Lessons for Inflammatory Bowel Disease
por: Honap, Sailish, et al.
Publicado: (2023)

Early Intervention in Ulcerative Colitis: Ready for Prime Time?
por: Solitano, Virginia, et al.
Publicado: (2020)

Evaluating Upadacitinib in the Treatment of Moderate-to-Severe Active Ulcerative Colitis: Design, Development, and Potential Position in Therapy
por: Napolitano, Maria, et al.
Publicado: (2022)

Risk-Benefit of IBD Drugs: A Physicians and Patients Survey
por: D’Amico, Ferdinando, et al.
Publicado: (2023)

PDE4 Inhibition and Inflammatory Bowel Disease: A Novel Therapeutic Avenue
por: Spadaccini, Marco, et al.
Publicado: (2017)

COVID-19 mRNA Vaccine Short-Term Safety in Patients With Inflammatory Bowel Disease
por: Spiera, Emily, et al.
Publicado: (2022)

Tofacitinib in the treatment of ulcerative colitis: efficacy and safety from clinical trials to real-world experience
por: D’Amico, Ferdinando, et al.
Publicado: (2019)

Key Strategies to Optimize Outcomes in Mild-to-Moderate Ulcerative Colitis
por: Solitano, Virginia, et al.
Publicado: (2020)

Steering a Course through the COVID-19 Pandemic: Should the SECURE-IBD Registry Influence Prescribing for Patients with Inflammatory Bowel Disease?
por: Gomes, Catarina Frias, et al.
Publicado: (2021)

Incidence and Patterns of COVID-19 Among Inflammatory Bowel Disease Patients From the Nancy and Milan Cohorts
por: Allocca, Mariangela, et al.
Publicado: (2020)

Ultrasound Elastography in Inflammatory Bowel Diseases: A Systematic Review of Accuracy Compared with Histopathological Assessment
por: Dal Buono, Arianna, et al.
Publicado: (2022)

International consensus on methodological issues in standardization of fecal calprotectin measurement in inflammatory bowel diseases
por: D'Amico, Ferdinando, et al.
Publicado: (2021)

Pursuing neutrophils: systematic scoping review on blood-based biomarkers as predictors of treatment outcomes in inflammatory bowel disease
por: Magalhaes, Diogo, et al.
Publicado: (2023)

Definition of mild to moderate ulcerative colitis in clinical trials: A systematic literature review
por: Caron, Bénédicte, et al.
Publicado: (2022)

Ocular Manifestations in Patients with Inflammatory Bowel Disease in the Biologics Era
por: Cuny, Alix, et al.
Publicado: (2022)

Inflammatory Bowel Disease and COVID-19 Vaccination: A Patients’ Survey
por: Caron, Bénédicte, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_a06g6te1uer486gjgg2aqh970m